Abstract
Hypertension represents the most common cardiovascular risk factor, affecting more than 25% of the adult population in developed societies. Although beta-blockers have been previously shown to effectively reduce blood pressure and have been used for hypertension treatment for over 40 years, their effect on cardiovascular morbidity and mortality in hypertensive patients remains controversial and their use in uncomplicated hypertension is currently still under debate. According to the previous recommendations beta-blockers should not be preferred as first-line therapy in hypertension patients. This review summarizes the current knowledge on application of beta-blockers in patients with hypertension and discusses the most recent guidelines of the European Society of Hypertension (2009) on beta-blockers applications.
Keywords: Hypertension, antihypertensive treatment, beta-blocker, cardiovascular risk, beta-blockers, blood pressure, carteolol, carvedilol, labetalol, nadolol, penbutolol, pindolol, propranolol, timolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, National Institute for Health and Clinical Excellence, ESH/ESC 2007, European Lacidipine Study on Atherosclerosis, Losar-tan Intervention For Endpoint, Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Low-ering Arm, International Verapamil-Trandolapril Study, Metoprolol Atherosclerosis Prevention in Hypertension, ACE inhibitors, Conduit Artery Function Evaluation, Canadian Hypertension Education Program, coronary artery disease CHF, congestive heart failure
Current Vascular Pharmacology
Title: Current Place of Beta-Blockers in the Treatment of Hypertension
Volume: 8 Issue: 6
Author(s): Agata Bielecka-Dabrowa, Wilbert S. Aronow, Jacek Rysz and Maciej Banach
Affiliation:
Keywords: Hypertension, antihypertensive treatment, beta-blocker, cardiovascular risk, beta-blockers, blood pressure, carteolol, carvedilol, labetalol, nadolol, penbutolol, pindolol, propranolol, timolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, National Institute for Health and Clinical Excellence, ESH/ESC 2007, European Lacidipine Study on Atherosclerosis, Losar-tan Intervention For Endpoint, Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Low-ering Arm, International Verapamil-Trandolapril Study, Metoprolol Atherosclerosis Prevention in Hypertension, ACE inhibitors, Conduit Artery Function Evaluation, Canadian Hypertension Education Program, coronary artery disease CHF, congestive heart failure
Abstract: Hypertension represents the most common cardiovascular risk factor, affecting more than 25% of the adult population in developed societies. Although beta-blockers have been previously shown to effectively reduce blood pressure and have been used for hypertension treatment for over 40 years, their effect on cardiovascular morbidity and mortality in hypertensive patients remains controversial and their use in uncomplicated hypertension is currently still under debate. According to the previous recommendations beta-blockers should not be preferred as first-line therapy in hypertension patients. This review summarizes the current knowledge on application of beta-blockers in patients with hypertension and discusses the most recent guidelines of the European Society of Hypertension (2009) on beta-blockers applications.
Export Options
About this article
Cite this article as:
Bielecka-Dabrowa Agata, S. Aronow Wilbert, Rysz Jacek and Banach Maciej, Current Place of Beta-Blockers in the Treatment of Hypertension, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563861
DOI https://dx.doi.org/10.2174/157016110793563861 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiobesity Therapy: Emerging Drugs and Targets
Current Medicinal Chemistry Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors
Current Medicinal Chemistry The Significance of Pain in Chronic Venous Disease and its Medical Treatment
Current Vascular Pharmacology Drugs Designed to Improve Endothelial Function: Effects on Erectile Dysfunction
Current Pharmaceutical Design Diabetes and Nutritional Screening in Post-Bariatric Patients
Current Diabetes Reviews Serotonin-2 Receptor Agonists as Novel Ocular Hypotensive Agents and their Cellular and Molecular Mechanisms of Action: Novel Drug Targets for Glaucoma Treatment
Current Drug Targets Could Additional Inhibitors of the Renin -Angiotensin System be Clinically Useful?
Current Hypertension Reviews Progress in Drug Treatment of Cerebral Edema
Mini-Reviews in Medicinal Chemistry The Molecular Basis of Susceptibility to Infection in Liver Cirrhosis
Current Medicinal Chemistry Modeling the Effect of Selected Cyclodextrins on Nifedipine Solubility
Current Drug Discovery Technologies Tenofovir-Related Nephropathies in HIV-Infected Patients
Current Vascular Pharmacology Phenotypic Screening for Pharmaceuticals Using Tissue Constructs
Current Pharmaceutical Biotechnology Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands
Current Cardiology Reviews Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Arterial Accelerated Aging in Dialysis Patients: The Clinical Impact of Vascular Calcification
Current Vascular Pharmacology A Study on the Specifications of Cold Pressed Colza Oil
Recent Patents on Food, Nutrition & Agriculture Cardiac Stem Cell Characteristics in Physiological and Pathological Conditions
Current Pharmaceutical Design Current Evidence Regarding Low-carb Diets for The Metabolic Control of Type-2 Diabetes
Current Diabetes Reviews Impaired Renal Autoregulation in Susceptible Models of Renal Disease
Current Vascular Pharmacology